U.S. Markets open in 7 hrs 41 mins

Novartis AG (NVS)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
77.03-0.03 (-0.04%)
At close: 4:02PM EDT
People also watch
GSKSNYAZNLLYABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close77.06
Open76.65
Bid0.00 x
Ask0.00 x
Day's Range76.60 - 77.04
52 Week Range66.93 - 83.58
Volume1,772,038
Avg. Volume2,687,012
Market Cap181.85B
Beta0.72
PE Ratio (TTM)28.96
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.72 (3.71%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com10 hours ago

    How Far Into the Drug Pipeline Should the FTC Reach?

    Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.

  • 5 Big Drugmakers With Important Catalysts in May
    Motley Fool14 hours ago

    5 Big Drugmakers With Important Catalysts in May

    Merck, Novartis, Novo Nordisk, Regeneron, and Sanofi await big FDA decisions in May.

  • Reuters3 days ago

    U.S. FDA approves Novartis' leukemia treatment

    The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday. AML is a cancer that originates in the bone marrow and progresses rapidly, resulting in an abnormal increase in white blood cells. Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said.